Neoleukin Therapeutics (NLTX) Competitors $18.55 -0.97 (-4.97%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. COGT, TYRA, VALN, MRVI, RLAY, GHRS, STOK, OPT, UPB, and KURAShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Cogent Biosciences (COGT), Tyra Biosciences (TYRA), Valneva (VALN), Maravai LifeSciences (MRVI), Relay Therapeutics (RLAY), GH Research (GHRS), Stoke Therapeutics (STOK), Opthea (OPT), Upstream Bio (UPB), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Cogent Biosciences Tyra Biosciences Valneva Maravai LifeSciences Relay Therapeutics GH Research Stoke Therapeutics Opthea Upstream Bio Kura Oncology Cogent Biosciences (NASDAQ:COGT) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, community ranking, risk, media sentiment, profitability, valuation and institutional ownership. Which has more risk & volatility, COGT or NLTX? Cogent Biosciences has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Do insiders & institutionals have more ownership in COGT or NLTX? 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is COGT or NLTX more profitable? Neoleukin Therapeutics' return on equity of -37.22% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -112.55% -60.44% Neoleukin Therapeutics N/A -37.22%-30.91% Does the MarketBeat Community believe in COGT or NLTX? Cogent Biosciences received 241 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 70.12% of users gave Cogent Biosciences an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes29170.12% Underperform Votes12429.88% Neoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Do analysts rate COGT or NLTX? Cogent Biosciences presently has a consensus price target of $14.00, indicating a potential upside of 181.12%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cogent Biosciences is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, COGT or NLTX? Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$192.41M-$1.84-2.71Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.96 Does the media prefer COGT or NLTX? In the previous week, Cogent Biosciences had 4 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for Cogent Biosciences and 2 mentions for Neoleukin Therapeutics. Cogent Biosciences' average media sentiment score of 1.28 beat Neoleukin Therapeutics' score of 0.37 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neoleukin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCogent Biosciences beats Neoleukin Therapeutics on 12 of the 16 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$174.33M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-5.968.9226.8419.71Price / SalesN/A250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book1.676.466.794.50Net Income-$57.56M$143.98M$3.23B$248.18M7 Day Performance19.60%3.04%4.07%1.14%1 Month Performance61.44%7.44%12.52%15.18%1 Year Performance-45.46%-2.46%16.83%6.55% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$18.55-5.0%N/A-42.6%$174.33MN/A-5.9690Gap UpHigh Trading VolumeCOGTCogent Biosciences2.3651 of 5 stars$5.13+6.7%$14.29+178.5%-32.3%$547.65MN/A-2.0780News CoveragePositive NewsAnalyst ForecastGap DownTYRATyra Biosciences1.7063 of 5 stars$10.26+1.7%$30.83+200.5%-46.7%$544.70MN/A-6.3720News CoveragePositive NewsAnalyst ForecastAnalyst RevisionVALNValneva2.1442 of 5 stars$6.45-0.3%$15.50+140.3%-27.5%$539.45M$169.58M-49.62700MRVIMaravai LifeSciences4.083 of 5 stars$2.12+7.1%$6.34+199.2%-78.8%$539.19M$259.19M-1.29610Gap UpRLAYRelay Therapeutics3.3293 of 5 stars$3.11+3.7%$17.67+468.1%-55.0%$533.19M$7.68M-1.19330Positive NewsGap DownGHRSGH Research2.5594 of 5 stars$10.16-2.1%$30.43+199.5%-6.3%$528.60MN/A-12.8610STOKStoke Therapeutics3.6463 of 5 stars$9.66+3.2%$25.60+165.0%-37.6%$527.41M$36.56M-4.60100Analyst RevisionGap DownOPTOpthea0.6676 of 5 stars$3.41+7.2%$1.33-60.9%-1.4%$524.84M$87,666.000.008Gap UpUPBUpstream Bio2.2283 of 5 stars$9.50+7.7%$56.50+494.7%N/A$511.04M$2.30M0.0038News CoverageKURAKura Oncology4.309 of 5 stars$6.09+5.7%$23.89+292.3%-71.3%$498.67M$67.99M-2.58130News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Cogent Biosciences Alternatives Tyra Biosciences Alternatives Valneva Alternatives Maravai LifeSciences Alternatives Relay Therapeutics Alternatives GH Research Alternatives Stoke Therapeutics Alternatives Opthea Alternatives Upstream Bio Alternatives Kura Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NLTX Stock Free NLTX Stock Alerts